Novartis’ shares fell 13% this week after the report of three separate late-stage asset failures. The impact went beyond the ...

Frazier’s life science fund has already benefited several successful biotechs, including Verona Pharma, which was acquired by ...

The polycythemia vera field is heating up, with Disc Medicine and Silence Therapeutics each advancing next-generation ...

A few months after a new CEO stepped up to helm Takeda, the drugmaker will now have to prepare for another leadership change ...

Newly solidified in their roles as the heads of CBER and CDER, Karim Mikahil and Michael Davis have been working for months ...

The enrollment pause comes after BHV-7000 failed to show efficacy in a midstage depression trial late last year. The news is ...

With multiple drug pricing initiatives like Most Favored Nation now in force, drugmakers have to reinvent their commercial ...

Encoded Therapeutics’ lead asset ETX101 is a gene therapy being tested for Dravet syndrome. Phase 1/2 data showed substantial ...

Despite falling short of analyst expectations, Tyra Biosciences is taking its cancer drug to registrational development for ...

The FDA’s proposal to offer 50% off application fees for drugs with early-stage trials conducted in the U.S. is unlikely to ...

The company is investing billions of dollars to construct a European biosimilar hub capable of supporting the rapid expansion ...

Months before the current biotech IPO boom, public investors began a more confident trek back into the sector, signaling the ...